Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington’s diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer’s diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson’s disease; ION464 for multiple system atrophy and Parkinson’s disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa.
Ionis Pharmaceuticals, Inc.
Unlock to Claim this listing
Add / Modify Company
3.9
Overall Excellence Rating
Industry
HealthcareCategory
Biotech & PharmaceuticalsESG/Ethical Impact
Ionis Pharmaceuticals’ environmental impact is demonstrated through its commitment to sustainable research and development practices. Through responsible laboratory procedures, resource-efficient operations, and eco-friendly supply chain management, the company underscores its dedication to minimizing its ecological footprint. Ionis Pharmaceuticals’ efforts to reduce waste generation, conserve resources, and adopt green technologies manifest its commitment to environmentally conscious practices that contribute to a more sustainable biopharmaceutical landscape.Ionis Pharmaceuticals’ social impact revolves around its mission to transform patient lives and contribute positively to healthcare. By developing innovative biopharmaceutical solutions, the company plays a pivotal role in addressing critical medical needs and improving patient outcomes. Additionally, Ionis Pharmaceuticals’ commitment to patient education, patient advocacy, and community engagement underscores its dedication to fostering positive societal change.Strong governance and ethical practices underpin Ionis Pharmaceuticals’ operations. The company adheres to rigorous standards of transparency, regulatory compliance, and ethical decision-making. Transparent communication about its products, clinical trials, and ethical considerations demonstrates Ionis Pharmaceuticals’ commitment to responsible governance, maintaining stakeholder trust, and upholding ethical standards.Ionis Pharmaceuticals’ financial sustainability is intrinsically linked to its commitment to innovation. The company’s investment in research and development drives advancements in biopharmaceutical solutions, contributing to improved patient care and scientific progress. By embracing strategic financial management and fostering innovation, Ionis Pharmaceuticals maintains long-term value creation while driving advancements in biopharmaceutical research and development.Ionis Pharmaceuticals’ ethical responsibility extends to its biopharmaceutical development practices. The company places patient safety, regulatory adherence, and ethical innovation at the forefront of its operations. By maintaining the highest standards of quality in its products and clinical research, Ionis Pharmaceuticals ensures ethical practices that prioritize patient well-being and contribute to the overall integrity of the biopharmaceutical industry.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us

Awards Received
2023
Revenues
$580,000,000.00
Website Traffic
Employee Rating
3.8
Customer Rating
3.8
Company Size
100-1000
ESG Risk Rating
3